Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.58 |
| ▸ | CYP19A1 | P11511 | 11/20 | 0.55 |
| ▸ | SHBG | P04278 | 1/20 | 0.53 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3753842 | 1.00 | CYP3A4 (0.58) | CYP3A4CYP19A1SHBGCYP17A1MEN1 | |
| SCHEMBL3753990 | 0.86 | SHBG (0.71) | CYP3A4CYP19A1SHBGCYP17A1MEN1 | |
| SCHEMBL3753985 | 0.86 | SHBG (0.71) | CYP3A4CYP19A1SHBGCYP17A1MEN1 | |
| SCHEMBL25863917 | 0.85 | CYP3A4 (0.62) | CYP3A4CYP19A1SHBGMEN1KMT2A | |
| SCHEMBL25863918 | 0.85 | CYP3A4 (0.62) | CYP3A4CYP19A1SHBGMEN1KMT2A | |
| SCHEMBL24102509 | 0.84 | CYP3A4 (0.80) | CYP3A4CYP19A1SHBGAR | |
| SCHEMBL7613139 | 0.84 | CYP3A4 (0.80) | CYP3A4CYP19A1SHBGAR | |
| SCHEMBL25863598 | 0.84 | CYP3A4 (0.80) | CYP3A4CYP19A1SHBGAR | |
| SCHEMBL24102536 | 0.84 | CYP3A4 (0.80) | CYP3A4CYP19A1SHBGAR | |
| SCHEMBL7613135 | 0.84 | CYP3A4 (0.80) | CYP3A4CYP19A1SHBGAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292184-A1 | 17BETA-CYANO-19-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE | BAYER SCHERING PHARMA AG (DE) | 2010-11-18 | — | — | US | claimed |
| US-20100292184-A1 | 17BETA-CYANO-19-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE | BAYER SCHERING PHARMA AG (DE) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292184-A1 | 17BETA-CYANO-19-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE | HSD17B11, HSD17B7, NR5A1 | CYP3A4 166/4885CYP19A1 14/4885SHBG 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.